← Back to all trials
Enrolling By Invitation
NCT06723015
Tau PET Outcomes With Anti-amyloid Immunotherapies
Conditions: Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Sex: All
Ages: 50 Years – 90 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 135
Sponsor: Mayo Clinic
Location: Mayo Clinic Rochester Minnesota
Summary
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Eligibility Criteria
Inclusion Criteria
* Age 50-90 years
* Male or female
* Mild cognitive impairment due to AD or mild AD
* Amyloid positive via CSF or PET
* Meets other eligibility criteria for anti-amyloid immunotherapy
* Subject or delegate provides informed consent
Exclusion Criteria
* Subjects unable to lie down without moving for 10 minutes.
* Women who are pregnant or cannot stop breast feeding for 24 hours.
* Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
Source: ClinicalTrials.gov (NCT06723015). StuddyBuddy aggregates publicly available trial information.